Which has stronger earnings & valuation, MGNX or BIOA?

MacroGenics has higher revenue and earnings than BioAge Labs. BioAge Labs is trading at a lower price-to-earnings ratio than MacroGenics, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio MacroGenics $149.50M 1.66 -$74.62M -$1.10 N/A BioAge Labs $10.32M 48.26 -$80.61M -$2.40 N/A

Is MGNX or BIOA more profitable?

MacroGenics has a net margin of -44.79% compared to BioAge Labs' net margin of -871.75%. BioAge Labs' return on equity of -29.40% beat MacroGenics' return on equity. Company Net Margins Return on Equity Return on Assets MacroGenics -44.79% -147.80% -28.40% BioAge Labs -871.75% -29.40% -27.26%

Does the media favor MGNX or BIOA?

In the previous week, BioAge Labs had 12 more articles in the media than MacroGenics. MarketBeat recorded 14 mentions for BioAge Labs and 2 mentions for MacroGenics. MacroGenics' average media sentiment score of 0.67 beat BioAge Labs' score of 0.20 indicating that MacroGenics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment MacroGenics 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive BioAge Labs 3 Very Positive mention(s) 2 Positive mention(s) 4 Neutral mention(s) 2 Negative mention(s) 1 Very Negative mention(s) Neutral

Does the media prefer JBIO or MGNX?

In the previous week, Jade Biosciences had 3 more articles in the media than MacroGenics. MarketBeat recorded 5 mentions for Jade Biosciences and 2 mentions for MacroGenics. Jade Biosciences' average media sentiment score of 0.93 beat MacroGenics' score of 0.67 indicating that Jade Biosciences is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Jade Biosciences 3 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive MacroGenics 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Which has preferable valuation and earnings, IVA or MGNX?

MacroGenics has higher revenue and earnings than Inventiva. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Inventiva $5.07M 184.77 -$400.67M N/A N/A MacroGenics $149.50M 1.66 -$74.62M -$1.10 N/A

Is IVA or MGNX more profitable?

Inventiva has a net margin of 0.00% compared to MacroGenics' net margin of -44.79%. Inventiva's return on equity of 0.00% beat MacroGenics' return on equity. Company Net Margins Return on Equity Return on Assets Inventiva N/A N/A N/A MacroGenics -44.79% -147.80% -28.40%

Does the media refer more to IVA or MGNX?

In the previous week, Inventiva had 1 more articles in the media than MacroGenics. MarketBeat recorded 3 mentions for Inventiva and 2 mentions for MacroGenics. MacroGenics' average media sentiment score of 0.67 beat Inventiva's score of 0.66 indicating that MacroGenics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Inventiva 1 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive MacroGenics 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media favor MGNX or ANRO?

In the previous week, Alto Neuroscience had 5 more articles in the media than MacroGenics. MarketBeat recorded 7 mentions for Alto Neuroscience and 2 mentions for MacroGenics. Alto Neuroscience's average media sentiment score of 1.05 beat MacroGenics' score of 0.67 indicating that Alto Neuroscience is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment MacroGenics 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Alto Neuroscience 4 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Do analysts prefer VYNE or MGNX?

MacroGenics has a consensus price target of $5.50, indicating a potential upside of 41.03%. Given MacroGenics' stronger consensus rating and higher possible upside, analysts clearly believe MacroGenics is more favorable than VYNE Therapeutics. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score VYNE Therapeutics 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 MacroGenics 1 Sell rating(s) 3 Hold rating(s) 3 Buy rating(s) 0 Strong Buy rating(s) 2.29

Does the media refer more to VYNE or MGNX?

In the previous week, VYNE Therapeutics and VYNE Therapeutics both had 2 articles in the media. MacroGenics' average media sentiment score of 0.67 beat VYNE Therapeutics' score of -0.36 indicating that MacroGenics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment VYNE Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral MacroGenics 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

MacroGenics (MGNX) Competitors

$3.90 +0.08 (+2.09%)

Closing price 08/4/2026 04:00 PM Eastern

Extended Trading

$3.96 +0.06 (+1.67%)

As of 07:44 AM Eastern

Compare

MGNX vs. BIOA, JBIO, IVA, ANRO, and VYNE

Should you buy MacroGenics stock or one of its competitors? MarketBeat compares MacroGenics with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with MacroGenics include BioAge Labs (BIOA), Jade Biosciences (JBIO), Inventiva (IVA), Alto Neuroscience (ANRO), and VYNE Therapeutics (VYNE).

How does MacroGenics compare to BioAge Labs?

MacroGenics (NASDAQ:MGNX) and BioAge Labs (NASDAQ:BIOA) are both small-cap healthcare companies, but which is the better stock? We will compare the two companies based on the strength of their valuation, dividends, media sentiment, analyst recommendations, institutional ownership, earnings, risk and profitability.

MacroGenics has a net margin of -44.79% compared to BioAge Labs' net margin of -871.75%. BioAge Labs' return on equity of -29.40% beat MacroGenics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
MacroGenics	-44.79%	-147.80%	-28.40%
BioAge Labs	-871.75%	-29.40%	-27.26%

MacroGenics presently has a consensus price target of $5.50, suggesting a potential upside of 41.03%. BioAge Labs has a consensus price target of $36.57, suggesting a potential upside of 226.53%. Given BioAge Labs' stronger consensus rating and higher possible upside, analysts clearly believe BioAge Labs is more favorable than MacroGenics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
MacroGenics	1 Sell rating(s)	3 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.29
BioAge Labs	1 Sell rating(s)	0 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.71

MacroGenics has higher revenue and earnings than BioAge Labs. BioAge Labs is trading at a lower price-to-earnings ratio than MacroGenics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
MacroGenics	$149.50M	1.66	-$74.62M	-$1.10	N/A
BioAge Labs	$10.32M	48.26	-$80.61M	-$2.40	N/A

96.9% of MacroGenics shares are owned by institutional investors. 13.6% of MacroGenics shares are owned by insiders. Comparatively, 17.5% of BioAge Labs shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

MacroGenics has a beta of 1.2, suggesting that its share price is 20% more volatile than the broader market. Comparatively, BioAge Labs has a beta of 0.94, suggesting that its share price is 6% less volatile than the broader market.

In the previous week, BioAge Labs had 12 more articles in the media than MacroGenics. MarketBeat recorded 14 mentions for BioAge Labs and 2 mentions for MacroGenics. MacroGenics' average media sentiment score of 0.67 beat BioAge Labs' score of 0.20 indicating that MacroGenics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
MacroGenics	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
BioAge Labs	3 Very Positive mention(s)	2 Positive mention(s)	4 Neutral mention(s)	2 Negative mention(s)	1 Very Negative mention(s)	Neutral

Summary

MacroGenics and BioAge Labs tied by winning 8 of the 16 factors compared between the two stocks.

How does MacroGenics compare to Jade Biosciences?

Jade Biosciences (NASDAQ:JBIO) and MacroGenics (NASDAQ:MGNX) are both small-cap healthcare companies, but which is the superior investment? We will contrast the two businesses based on the strength of their analyst recommendations, valuation, profitability, dividends, institutional ownership, media sentiment, risk and earnings.

96.9% of MacroGenics shares are held by institutional investors. 23.1% of Jade Biosciences shares are held by company insiders. Comparatively, 13.6% of MacroGenics shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Jade Biosciences presently has a consensus target price of $51.57, suggesting a potential upside of 141.55%. MacroGenics has a consensus target price of $5.50, suggesting a potential upside of 41.03%. Given Jade Biosciences' stronger consensus rating and higher possible upside, equities analysts clearly believe Jade Biosciences is more favorable than MacroGenics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Jade Biosciences	1 Sell rating(s)	1 Hold rating(s)	6 Buy rating(s)	2 Strong Buy rating(s)	2.90
MacroGenics	1 Sell rating(s)	3 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.29

In the previous week, Jade Biosciences had 3 more articles in the media than MacroGenics. MarketBeat recorded 5 mentions for Jade Biosciences and 2 mentions for MacroGenics. Jade Biosciences' average media sentiment score of 0.93 beat MacroGenics' score of 0.67 indicating that Jade Biosciences is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Jade Biosciences	3 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
MacroGenics	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Jade Biosciences has a beta of 1.49, meaning that its stock price is 49% more volatile than the broader market. Comparatively, MacroGenics has a beta of 1.2, meaning that its stock price is 20% more volatile than the broader market.

Jade Biosciences has a net margin of 0.00% compared to MacroGenics' net margin of -44.79%. Jade Biosciences' return on equity of -51.34% beat MacroGenics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Jade Biosciences	N/A	-51.34%	-47.32%
MacroGenics	-44.79%	-147.80%	-28.40%

MacroGenics has higher revenue and earnings than Jade Biosciences. Jade Biosciences is trading at a lower price-to-earnings ratio than MacroGenics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Jade Biosciences	N/A	N/A	-$127.41M	-$2.02	N/A
MacroGenics	$149.50M	1.66	-$74.62M	-$1.10	N/A

Summary

Jade Biosciences beats MacroGenics on 10 of the 16 factors compared between the two stocks.

How does MacroGenics compare to Inventiva?

Inventiva (NASDAQ:IVA) and MacroGenics (NASDAQ:MGNX) are both small-cap healthcare companies, but which is the better stock? We will contrast the two companies based on the strength of their media sentiment, institutional ownership, dividends, risk, analyst recommendations, profitability, valuation and earnings.

MacroGenics has higher revenue and earnings than Inventiva.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Inventiva	$5.07M	184.77	-$400.67M	N/A	N/A
MacroGenics	$149.50M	1.66	-$74.62M	-$1.10	N/A

Inventiva has a beta of 0.7, suggesting that its stock price is 30% less volatile than the broader market. Comparatively, MacroGenics has a beta of 1.2, suggesting that its stock price is 20% more volatile than the broader market.

19.1% of Inventiva shares are owned by institutional investors. Comparatively, 96.9% of MacroGenics shares are owned by institutional investors. 32.0% of Inventiva shares are owned by company insiders. Comparatively, 13.6% of MacroGenics shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Inventiva presently has a consensus price target of $16.56, indicating a potential upside of 267.09%. MacroGenics has a consensus price target of $5.50, indicating a potential upside of 41.03%. Given Inventiva's stronger consensus rating and higher probable upside, analysts plainly believe Inventiva is more favorable than MacroGenics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Inventiva	1 Sell rating(s)	0 Hold rating(s)	7 Buy rating(s)	3 Strong Buy rating(s)	3.09
MacroGenics	1 Sell rating(s)	3 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.29

In the previous week, Inventiva had 1 more articles in the media than MacroGenics. MarketBeat recorded 3 mentions for Inventiva and 2 mentions for MacroGenics. MacroGenics' average media sentiment score of 0.67 beat Inventiva's score of 0.66 indicating that MacroGenics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Inventiva	1 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
MacroGenics	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Inventiva has a net margin of 0.00% compared to MacroGenics' net margin of -44.79%. Inventiva's return on equity of 0.00% beat MacroGenics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Inventiva	N/A	N/A	N/A
MacroGenics	-44.79%	-147.80%	-28.40%

Summary

Inventiva beats MacroGenics on 10 of the 15 factors compared between the two stocks.

How does MacroGenics compare to Alto Neuroscience?

MacroGenics (NASDAQ:MGNX) and Alto Neuroscience (NYSE:ANRO) are both small-cap healthcare companies, but which is the superior business? We will contrast the two companies based on the strength of their risk, media sentiment, dividends, profitability, analyst recommendations, valuation, institutional ownership and earnings.

MacroGenics has a beta of 1.2, meaning that its stock price is 20% more volatile than the broader market. Comparatively, Alto Neuroscience has a beta of 1.06, meaning that its stock price is 6% more volatile than the broader market.

In the previous week, Alto Neuroscience had 5 more articles in the media than MacroGenics. MarketBeat recorded 7 mentions for Alto Neuroscience and 2 mentions for MacroGenics. Alto Neuroscience's average media sentiment score of 1.05 beat MacroGenics' score of 0.67 indicating that Alto Neuroscience is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
MacroGenics	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Alto Neuroscience	4 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

96.9% of MacroGenics shares are owned by institutional investors. 13.6% of MacroGenics shares are owned by insiders. Comparatively, 11.3% of Alto Neuroscience shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

MacroGenics presently has a consensus price target of $5.50, indicating a potential upside of 41.03%. Alto Neuroscience has a consensus price target of $35.25, indicating a potential upside of 23.90%. Given MacroGenics' higher probable upside, research analysts plainly believe MacroGenics is more favorable than Alto Neuroscience.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
MacroGenics	1 Sell rating(s)	3 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.29
Alto Neuroscience	2 Sell rating(s)	1 Hold rating(s)	8 Buy rating(s)	0 Strong Buy rating(s)	2.55

Alto Neuroscience has a net margin of 0.00% compared to MacroGenics' net margin of -44.79%. Alto Neuroscience's return on equity of -47.22% beat MacroGenics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
MacroGenics	-44.79%	-147.80%	-28.40%
Alto Neuroscience	N/A	-47.22%	-38.81%

Alto Neuroscience has lower revenue, but higher earnings than MacroGenics. Alto Neuroscience is trading at a lower price-to-earnings ratio than MacroGenics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
MacroGenics	$149.50M	1.66	-$74.62M	-$1.10	N/A
Alto Neuroscience	N/A	N/A	-$63.24M	-$2.42	N/A

Summary

MacroGenics beats Alto Neuroscience on 8 of the 15 factors compared between the two stocks.

How does MacroGenics compare to VYNE Therapeutics?

VYNE Therapeutics (NASDAQ:VYNE) and MacroGenics (NASDAQ:MGNX) are both small-cap healthcare companies, but which is the superior business? We will compare the two companies based on the strength of their profitability, valuation, risk, dividends, earnings, analyst recommendations, institutional ownership and media sentiment.

83.8% of VYNE Therapeutics shares are held by institutional investors. Comparatively, 96.9% of MacroGenics shares are held by institutional investors. 3.0% of VYNE Therapeutics shares are held by company insiders. Comparatively, 13.6% of MacroGenics shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

MacroGenics has a net margin of -44.79% compared to VYNE Therapeutics' net margin of -4,726.21%. VYNE Therapeutics' return on equity of -70.42% beat MacroGenics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
VYNE Therapeutics	-4,726.21%	-70.42%	-63.46%
MacroGenics	-44.79%	-147.80%	-28.40%

VYNE Therapeutics has a beta of 2, meaning that its stock price is 100% more volatile than the broader market. Comparatively, MacroGenics has a beta of 1.2, meaning that its stock price is 20% more volatile than the broader market.

MacroGenics has a consensus price target of $5.50, indicating a potential upside of 41.03%. Given MacroGenics' stronger consensus rating and higher possible upside, analysts clearly believe MacroGenics is more favorable than VYNE Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
VYNE Therapeutics	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
MacroGenics	1 Sell rating(s)	3 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.29

In the previous week, VYNE Therapeutics and VYNE Therapeutics both had 2 articles in the media. MacroGenics' average media sentiment score of 0.67 beat VYNE Therapeutics' score of -0.36 indicating that MacroGenics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
VYNE Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral
MacroGenics	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

VYNE Therapeutics has higher earnings, but lower revenue than MacroGenics. VYNE Therapeutics is trading at a lower price-to-earnings ratio than MacroGenics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
VYNE Therapeutics	$570K	33.29	-$26.48M	-$0.38	N/A
MacroGenics	$149.50M	1.66	-$74.62M	-$1.10	N/A

Summary

MacroGenics beats VYNE Therapeutics on 10 of the 15 factors compared between the two stocks.

Get MacroGenics News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding MGNX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

MGNX vs. The Competition

Export

Metric	MacroGenics	Biotechnology Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$242.81M	$3.52B	$6.83B	$12.77B
Dividend Yield	N/A	3.77%	2.60%	10.01%
P/E Ratio	-3.55	7.32	279.15	25.53
Price / Sales	1.66	1,279.23	591.00	92.31
Price / Cash	N/A	103.44	72.11	49.39
Price / Book	4.43	17.25	13.02	6.11
Net Income	-$74.62M	-$12.52M	$3.48B	$347.58M
7 Day Performance	6.27%	3.63%	3.39%	4.91%
1 Month Performance	-17.20%	-5.38%	-2.80%	-2.06%
1 Year Performance	130.77%	49.44%	73.07%	21.03%

MacroGenics Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
MGNX MacroGenics	2.5241 of 5 stars	$3.90 +2.1%	$5.50 +41.0%	+137.8%	$242.81M	$149.50M	N/A	430
BIOA BioAge Labs	3.2004 of 5 stars	$21.92 +5.0%	$43.50 +98.4%	+153.4%	$974.34M	$8.99M	N/A	N/A	Analyst Forecast
JBIO Jade Biosciences	3.2555 of 5 stars	$19.70 -1.3%	$51.57 +161.8%	+192.9%	$972.39M	N/A	N/A	20	Positive News
IVA Inventiva	2.4182 of 5 stars	$4.64 +0.9%	$16.56 +256.8%	+39.2%	$963.76M	$4.48M	N/A	100
ANRO Alto Neuroscience	2.3193 of 5 stars	$27.40 -1.7%	$35.25 +28.6%	+826.7%	$961.47M	N/A	N/A	N/A	Positive News Upcoming Earnings

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:MGNX) was last updated on 8/5/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

MacroGenics (MGNX) Competitors

MGNX vs. BIOA, JBIO, IVA, ANRO, and VYNE

How does MacroGenics compare to BioAge Labs?

Summary

How does MacroGenics compare to Jade Biosciences?

Summary

How does MacroGenics compare to Inventiva?

Summary

How does MacroGenics compare to Alto Neuroscience?

Summary

How does MacroGenics compare to VYNE Therapeutics?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

MGNX vs. The Competition

MacroGenics Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

MacroGenics (MGNX) Competitors

MGNX vs. BIOA, JBIO, IVA, ANRO, and VYNE

How does MacroGenics compare to BioAge Labs?

Is MGNX or BIOA more profitable?

Do analysts prefer MGNX or BIOA?

Which has stronger earnings & valuation, MGNX or BIOA?

Do institutionals and insiders have more ownership in MGNX or BIOA?

Which has more risk & volatility, MGNX or BIOA?

Does the media favor MGNX or BIOA?

Summary

How does MacroGenics compare to Jade Biosciences?

Do institutionals & insiders have more ownership in JBIO or MGNX?

Do analysts rate JBIO or MGNX?

Does the media prefer JBIO or MGNX?

Which has more risk & volatility, JBIO or MGNX?

Is JBIO or MGNX more profitable?

Which has stronger valuation and earnings, JBIO or MGNX?

Summary

How does MacroGenics compare to Inventiva?

Which has preferable valuation and earnings, IVA or MGNX?

Which has more risk and volatility, IVA or MGNX?

Do institutionals and insiders believe in IVA or MGNX?

Do analysts rate IVA or MGNX?

Does the media refer more to IVA or MGNX?

Is IVA or MGNX more profitable?

Summary

How does MacroGenics compare to Alto Neuroscience?

Which has more volatility and risk, MGNX or ANRO?

Does the media favor MGNX or ANRO?

Do insiders and institutionals believe in MGNX or ANRO?

Do analysts recommend MGNX or ANRO?

Is MGNX or ANRO more profitable?

Which has preferable earnings & valuation, MGNX or ANRO?

Summary

How does MacroGenics compare to VYNE Therapeutics?

Do insiders & institutionals believe in VYNE or MGNX?

Is VYNE or MGNX more profitable?

Which has more volatility and risk, VYNE or MGNX?

Do analysts prefer VYNE or MGNX?

Does the media refer more to VYNE or MGNX?

Which has better valuation and earnings, VYNE or MGNX?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

MGNX vs. The Competition

MacroGenics Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools